South Korea

AI Citation Summary

• Country: South Korea
• Product line: Medical devices
• Regulator / source: Primary regulator - Ministry of Food and Drug Safety (MFDS, 식품의약품안전처), with technical/scientific review support from the National Institute of Food and Drug Safety Evaluation (NIFDS)
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in South Korea are regulated by the Ministry of Food and Drug Safety (MFDS, 식품의약품안전처) under the Medical Devices Act (의료기기법, 2003, as amended), which sorts every product into one of four risk classes (I–IV) and routes it to one of three authorization forms — notification (신고) for Class I, certification (인증) for eligible Class II devices with a registered predicate, or approval/license (허가) for the remaining Class II devices and all Class III/IV devices. A foreign manufacturer cannot register directly with MFDS: it must appoint a Korea License Holder (KLH) — its own Korean subsidiary, a local distributor, or an independent third-party KLH service — which holds the Import Item License (수입품목허가) in its own name and controls who may import the device. Realistic end-to-end timelines run from roughly 1–2 weeks for a Class I notification to 15–24 months for a Class IV approval once RFI rounds are included, and the Import Item License itself carries no fixed expiry, though it remains subject to periodic post-market re-evaluation and to keeping the underlying KGMP/ISO 13485 evidence current.
• Key fees: Typical total cost - Official MFDS application/review fees are modest (roughly KRW 100,000–2,000,000 depending on class); all-in project budgets including KLH service fees, Korean translation, and consulting commonly run USD 50,000–120,000 for a Class III device with ISO 13485 already in place, and USD 100,000–300,000+ for a Class IV device requiring new clinical data. 【待核验：现行 MFDS 官方费率表未能在本轮直接抓取核实，建议以 MFDS 官网费率计算器逐项复核】
• Local requirement: Local agent / certificate holder - Mandatory Korea License Holder (KLH) — an own Korean subsidiary, a local distributor, or an independent third-party KLH firm — holds the Import Item License in its own name; a foreign manufacturer cannot hold it directly
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Quick Answer

Medical devices sold in South Korea are regulated by the Ministry of Food and Drug Safety (MFDS, 식품의약품안전처) under the Medical Devices Act (의료기기법, 2003, as amended), which sorts every product into one of four risk classes (I–IV) and routes it to one of three authorization forms — notification (신고) for Class I, certification (인증) for eligible Class II devices with a registered predicate, or approval/license (허가) for the remaining Class II devices and all Class III/IV devices. A foreign manufacturer cannot register directly with MFDS: it must appoint a Korea License Holder (KLH) — its own Korean subsidiary, a local distributor, or an independent third-party KLH service — which holds the Import Item License (수입품목허가) in its own name and controls who may import the device. Realistic end-to-end timelines run from roughly 1–2 weeks for a Class I notification to 15–24 months for a Class IV approval once RFI rounds are included, and the Import Item License itself carries no fixed expiry, though it remains subject to periodic post-market re-evaluation and to keeping the underlying KGMP/ISO 13485 evidence current.

Quick Reference

Market Overview

• Population: Approximately 52 million (2024); one of the fastest-aging populations among major medical device markets, driving sustained demand for chronic-disease management, diagnostics, and elderly-care devices.
• Healthcare System: Universal health insurance under the National Health Insurance Service (NHIS); a dual public/private hospital system with a globally competitive private-hospital and medical-tourism sector. Domestic device manufacturers (Samsung Medison, Osstem Implant, Vatech, Lunit, Seegene, SD Biosensor) are strong, technically sophisticated competitors, not just low-cost alternatives.
• Market Characteristics: Market size approximately KRW 10 trillion (roughly USD 7.5 billion) as of the most recent full-year figures available — Asia's fourth-largest medical device market. Imports account for roughly half of the market by value. The government actively promotes domestic device exports while maintaining strict import-side regulation; AI-based and digital-health devices are the fastest-growing segment.
• Regulatory Maturity: High. MFDS runs a well-established, IMDRF/GHTF-aligned regulatory system, and has moved quickly on digital-health regulation — the Digital Medical Products Act (디지털의료제품법, DMPA) became fully effective January 24, 2026, formally separating software/AI-based "digital medical products" from general hardware-device rules for the first time. Review timelines are comparatively predictable versus regional peers once a dossier is complete.

Regulatory Authority and Legal Framework

• Competent Authority: Ministry of Food and Drug Safety (MFDS, 식품의약품안전처). Scientific/technical review is supported by the National Institute of Food and Drug Safety Evaluation (NIFDS), and Class II devices with a registered predicate can be routed to one of six MFDS-designated third-party reviewers rather than MFDS itself.
• Official Portals: https://www.mfds.go.kr/eng (English portal); product-level submissions and UDI data go through UDIPORTAL (의료기기 통합정보시스템) and the Import Item License system (수입품목허가시스템).
• Governing Regulations:
  • 의료기기법 — Medical Devices Act, enacted 2003, with multiple subsequent revisions; the top-level statute.
  • 의료기기법 시행령 / 시행규칙 — Enforcement Decree and Enforcement Rules of the Medical Devices Act.
  • 의료기기 허가·신고·심사 등에 관한 규정 — Regulations on Licensing, Notification, and Review of Medical Devices (MFDS Notice), the operative rulebook for classification, notification, certification, and approval procedures; periodically revised — MFDS Notice 2026-6 is the most recent significant update, clarifying the boundaries between combination, integrated, and single-use devices and formally defining Software as a Medical Device (SaMD).
  • 의료기기 표시·기재 등에 관한 규정 (MFDS Notice 2022-110) — the Korean-language labeling and IFU guideline; see Element 7.
  • 의료기기 제조 및 품질관리 기준 (KGMP, 품질관리기준) — the Korean GMP standard.
  • 디지털의료제품법 (Digital Medical Products Act, DMPA) — fully effective January 24, 2026; separates "digital medical products" (SaMD, AI-based devices, digital therapeutics) from "digital health support products" for the first time, with distinct labeling articles (Article 22 for digital medical device software; Articles 33–35 for digital medical/health support devices).
  • 인체이식형·생명유지용 의료기기 등의 관리에 관한 규정 and related MFDS notices on combination-product classification — MFDS issued dedicated combination-product review guidelines in November 2021, followed by a classification casebook in April 2022.

Element 1 — Device Classification and Risk-Based Pathway Branching

Classification is the single decision that determines the authorization form, who reviews the application, whether a predicate/substantial-equivalence (S.E.) route is available, and how long the process realistically takes. Korea's four-class scheme is closely aligned with the GHTF/IMDRF risk model, so cross-mapping to EU and FDA classes is directional but not automatic — always confirm classification against MFDS's own product classification catalogue rather than assuming parity with a device's EU/FDA class.

Branching logic in practice: the presence of a substantial equivalent (S.E.) — an already-registered Korean product with matching intended use, mechanism of action, and materials — is what actually splits a Class II or III device between the faster certification/expedited-approval track and the slower Safety and Efficacy Review (SER) track, not the class number alone. Predicate assessment itself is a formal review against 5–6 defined comparison categories, so a device that looks similar to a marketed product on paper can still fail S.E. status on a technical point and get routed to the slower track. IVDs use this same four-class structure with IVD-specific predicate criteria — see the IVD section below.

Element 2 — License-Holder Logic: the Korea License Holder (KLH) System

This is the decision that shapes commercial control in Korea more than any other regulatory choice, and it deserves to be treated as a structural business decision, not a paperwork formality.

• A Korea License Holder is mandatory. A foreign manufacturer cannot apply for or hold an Import Item License directly. The KLH is a Korean-incorporated entity that submits the application, is named as the license holder of record, and becomes the manufacturer's legal in-country point of contact for MFDS.
• The KLH — not the foreign manufacturer — is the legal owner of the registration. The Import Item License is issued in the KLH's name, and the KLH "controls who may import the registered device" — a structurally different position from China, where the certificate is issued in the foreign manufacturer's own name with the local agent as a liable-but-non-owning party. Korea's model sits closer to Indonesia's or the Philippines' distributor-held model than to China's or the EU's manufacturer/authorized-representative model.

• Switching KLH has real consequences. Changing the license holder generally requires a formal license-holder-change filing with MFDS, or in some cases a fresh registration citing substantial equivalence to the existing marketed product — neither is instantaneous, and product supply should not be assumed to continue uninterrupted during the transition. This is the single most consequential fact a foreign manufacturer needs to internalize before signing a distribution agreement: who imports the product and who holds the license are two separable roles, and conflating them (by defaulting to "our distributor will also be our KLH" without weighing the alternative) is the most common structuring mistake foreign teams make entering Korea.
• Import Item License vs. Import Business License — do not conflate them. The Import Item License (수입품목허가) is the per-product certificate discussed throughout this page and does not expire. Separately, the KLH itself must hold a general Import Business License (수입업허가) — its own qualification to operate as a medical device importer — which some secondary sources describe as subject to a periodic renewal cycle at the business-license level. 【待核验：进口业许可（企业资质层）与进口品目许可（产品证书层）的续期周期存在二手来源表述差异，建议向本地 KLH 或 MFDS 直接核实】
• KLH qualification requirements: must hold a valid Import Business License, designate a Quality and Safety Manager (품질책임자) meeting MFDS qualification criteria (pharmacist, medical device engineer, or a relevant science/engineering degree with required experience), and demonstrate the operational capacity to fulfill adverse-event reporting and recall obligations — see Element 4.

Element 3 — Certificate Validity and Review-Timeline Ranges

Why the statutory figure and the real-world figure diverge: the official working-day targets published by MFDS and reflected in third-party regulatory summaries cover only the active review clock — they exclude dossier pre-screening, administrative acceptance, and, most significantly, every round of RFI ("보완요청") clock-stop, which is routine for Class III/IV submissions and common for Class II approval-track products. Budget the practical range as the working baseline, not the statutory day-count, and add the GMP on-site inspection window separately if MFDS elects to inspect rather than accept ISO 13485/MDSAP-equivalent evidence.

Element 4 — KLH In-Country Obligations

Holding an Import Item License is not a one-time compliance event. The KLH carries continuing operational duties for as long as the product remains on the Korean market:

Practically, the KLH is not a mailbox function — a foreign manufacturer that treats KLH selection purely as a low-stakes administrative formality is under-pricing the risk of a botched RFI response, a late adverse-event report, or a failed periodic re-evaluation, any of which can jeopardize continued market access.

Element 5 — Fee Model: One-Time vs. Recurring

Korea's fee structure mixes modest government application/review fees with recurring commercial costs that dominate the real project budget. There is no single official "all-in" total because it depends heavily on class, KLH structure, and whether new clinical or local testing data is required.

【待核验：以上官方申请费具体数值为二手来源汇总，本轮未能直接抓取 MFDS 官方费率计算器核验，建议以现行 MFDS 官方费率表为准】

Element 6 — Registration Forms: Notification vs. Certification vs. Approval

Korea's system has three authorization forms, each with a materially different legal character:

Two supplementary mechanisms sit alongside the standard tracks:

• 혁신의료기기 (Innovative Medical Device) designation — analogous to FDA Breakthrough Device status; devices addressing an unmet clinical need with genuine technological innovation can receive priority review and rolling-review support.
• Abbreviated Review (약식심사) — a defined-scope fast lane keyed to prior FDA clearance/approval for eligible product categories; see Element 8. This is not a universal shortcut and must be confirmed category-by-category.

Element 7 — Special Requirements

Korean-Language Labeling and IFU

This is the single largest Korea-specific search-demand cluster on this page, and it deserves to be treated as a first-class compliance workstream, not an afterthought translated at the last minute.

• Korean is mandatory on every medical device label and IFU. Per MFDS Notice 2022-110 (의료기기 표시·기재에 관한 규정), labels must be built to Korean regulatory requirements directly — a straight translation of an existing English or CE label is explicitly not sufficient, because the mandated content set and approved warning phrasings are Korea-specific.

• IFU content: Korean-language instructions for use must cover device identification (mirroring the label), intended use/indications, contraindications, warnings/precautions, known adverse events, step-by-step operating instructions, storage/handling, sterilization procedure (if applicable), maintenance/cleaning, disposal, and manufacturing-date/KLH contact information. Bilingual Korean+English IFUs are acceptable provided Korean is the primary, controlling language and is displayed at equal or larger prominence.
• Electronic IFU (eIFU): accepted for some device categories, but a physical label on the device or package is still required regardless of whether the full IFU is delivered electronically — eIFU does not eliminate the physical labeling obligation.
• UDI labeling: Korea runs its own national UDI system (KUDI), aligned with the GS1 framework and integrated into UDIPORTAL. Rollout has been phased by class since 2019 — Class IV devices were first required to carry UDI, with Class III and Class II progressively brought into scope; UDI data must be registered in the MFDS UDI database and referenced consistently across notification/certification/approval and change filings.
• Practical implication: budget a dedicated Korean regulatory-labeling review pass distinct from your CE/FDA labeling package — direct reuse is partial at best, both because of the Korea-specific mandatory content set and because MFDS maintains its own list of approved Korean warning phrasings that generic translation will not reliably reproduce.

Local Type Testing

This is the second-largest Korea-specific search-demand cluster on this page.

• When local testing is required: implantable and life-supporting devices, advanced diagnostic systems, and genuinely novel products (new technology, no established Korean predicate, new materials) are the categories most likely to require local performance/safety testing rather than relying solely on foreign lab data. Devices with electrical components additionally require electrical-safety testing (IEC 60601 series) and EMC testing consistent with Korean requirements.
• MFDS-recognized testing and certification bodies:

• When foreign test reports are accepted instead of local testing: existing foreign test data can generally be accepted in place of a fresh local test if it meets MFDS's specific testing criteria and was generated by a recognized/accredited laboratory (e.g., ILAC-MRA-accredited). MFDS retains discretion to request supplemental local testing regardless of foreign data quality, particularly for genuinely novel technology, where documentation does not clearly demonstrate conformity to the Korean standard cited, or where a Korean predicate simply does not exist to benchmark against.
• Timeline and cost: local testing itself, where required, commonly takes 4–12 weeks depending on device complexity — this runs in parallel with, but adds real lead time to, the overall registration timeline in Element 3, and is a common cause of missed internal launch dates when not planned for from the outset.

Combination Products

Korea regulates combination products by determining a Primary Mode of Action (PMOA) — the single mode of action that provides the product's most important therapeutic effect — which decides whether the Pharmaceutical Affairs Act (as a drug) or the Medical Devices Act (as a device, following this page's pathway) applies. MFDS issued dedicated combination-product review guidelines in November 2021, followed by a classification casebook comparing domestic and overseas classification outcomes in April 2022.

Practical implication: classification should be resolved early and, where genuinely ambiguous, confirmed with MFDS before committing to a dossier strategy — a product wrongly assumed to be device-led that is later reclassified as drug-led (or vice versa) means restarting under an entirely different statute, reviewing division, and evidence package.

Element 8 — Shortcut Pathways for Overseas Companies: What FDA/CE/NMPA Approval Actually Unlocks

Quick Assessment

What FDA approval unlocks

• Abbreviated Review (약식심사): for product categories explicitly within its scope, MFDS allows an application supported by FDA 510(k) clearance or PMA approval to bypass detailed technical-document review in favor of a recognition-based assessment against the FDA decision itself — compressing a 12–18 month standard review toward roughly 4–8 months with substantially reduced documentation. Eligibility must be confirmed category-by-category against MFDS's licensing/review guidelines or through the 사전검토 (pre-review consultation) system before committing resources.
• Clinical/technical evidence reuse: even outside Abbreviated Review scope, FDA 510(k) Summaries, De Novo Decision Summaries, and PMA clinical data are accepted as supporting evidence in standard MFDS technical review, reducing RFI rounds versus a dossier with no reference-market data at all.
• Substantial-equivalence framing: FDA's substantial-equivalence logic is compatible with how MFDS assesses predicate/S.E. status for the certification track described in Elements 1 and 6, making a well-documented 510(k) file a useful structural starting point for the Korean predicate argument (though MFDS makes its own independent determination).

What CE approval unlocks

• Direct reuse of IMDRF-structured technical documentation: because CE MDR/IVDR technical files and MFDS's expected dossier structure both trace back to the IMDRF Common Submission Technical File (STED) format, a CE technical file can be reorganized into a Korean submission without a full rebuild — commonly cited as saving on the order of 30–50% of documentation preparation time.
• Overseas-marketing proof: MFDS requires evidence of overseas marketing status (a Certificate of Free Sale, FSC, from a government authority), and a CE certificate — provided it is a Notified Body–issued certificate rather than a Class I self-declaration — is often part of that evidentiary chain. A CE certificate is not itself a substitute for a government-issued FSC; confirm current KLH-level practice on this point before assuming CE alone satisfies the requirement.
• Reviewer confidence, not formal acceleration: products with CE certification are generally viewed favorably in MFDS reviewers' technical assessment and tend to draw fewer queries, but this does not compress the statutory review clock the way Abbreviated Review does for FDA-eligible categories.

What it does NOT unlock

• No formal reliance or mutual-recognition mechanism with either the EU or the US outside the narrow, category-specific Abbreviated Review scope for FDA data.
• No waiver of the Korea License Holder requirement, Korean-language labeling, KGMP evidence, or the periodic re-evaluation cycle — every product still needs a KLH and Korean-compliant labeling regardless of reference-market approval.
• No classification mapping guarantee — an FDA Class II (510(k)) or EU Class IIa device does not automatically land in the equivalent Korean class; MFDS makes an independent classification determination.
• No timeline guarantee outside eligible Abbreviated Review categories — do not build a Korea launch plan assuming FDA/CE data will compress the standard timeline unless Abbreviated Review eligibility has been explicitly confirmed for that product category.
• NMPA carries essentially no formal or informal weight in MFDS review; manufacturers with both NMPA and FDA/CE approvals should lead with the FDA/CE evidence in Korean submissions.

IVD-Specific Requirements

• IVDs follow the same four-class GHTF-aligned structure as general devices, but predicate/S.E. assessment criteria and clinical-evidence expectations are IVD-specific.
• Bridging evidence for foreign clinical data: MFDS accepts foreign clinical/analytical data but, for companion diagnostics and comparable products, expects bridging evidence demonstrating that ethnic/population factors do not materially affect performance parameters (e.g., cut-off values, limit of detection) for the Korean population.
• KLH duties specific to IVDs: the KLH for an IVD product must file monthly supply reports through the integrated MFDS system, on top of the general KLH obligations in Element 4.
• Predicate rigor: predicate assessment for IVDs is a formal review against defined comparison categories — a superficially similar existing product is not automatically accepted as a valid predicate.

SaMD and AI/Digital Health Medical Device Software Requirements

• Regulatory head start: Korea issued some of the world's earliest dedicated guidance for AI-based medical device software, starting in 2019 and updated in 2021, giving MFDS reviewers more institutional experience with algorithm-based submissions than most regional peers.
• Digital Medical Products Act (DMPA, 디지털의료제품법) — fully effective January 24, 2026: this is the most consequential recent regulatory development for software in Korea. The DMPA formally separates "digital medical products" (SaMD, AI-based diagnostic/decision-support software, digital therapeutics) from "digital health support products" (lower-risk wellness/support software) for the first time, with distinct labeling requirements: Article 22 governs labeling for digital medical device software specifically, while Articles 33–35 govern digital medical/health support devices more broadly.
• Classification logic for software: MFDS first determines whether software embedded in a PC, mobile device, or general-purpose hardware qualifies as SaMD at all, then assesses the scope of its intended application — critically, whether the target condition is identifiable against the International Classification of Diseases (ICD) or the Korean Standard Classification of Disease (KCD), which is a key factor in whether the product is treated as a regulated digital medical product versus a lower-risk digital health support product.
• Digital therapeutics (DTx): MFDS defines DTx as an evidence-based intervention delivered directly to patients for prevention, control, or treatment of a medical condition, usable independently or alongside existing treatment. As of the most recent count available, five DTx products had received MFDS approval, and Korea's Ministry of Health and Welfare (MOHW) is actively exploring reimbursement pathways for the category — approval and reimbursement remain separate gates, consistent with the general market-access pattern described in Market Access Channels below.
• Documentation expectations: AI-based medical device submissions must include algorithm validation data, training-dataset descriptions, and documentation of any continuous-learning mechanism; cybersecurity documentation for connected/networked software is an explicit review focus area, reinforced under the DMPA framework.
• Practical implication: foreign SaMD/DTx applicants should budget for a Korea-specific software dossier and labeling pass distinct from a CE MDR or FDA 510(k)/De Novo software package — direct one-to-one reuse is partial, both because of DMPA's new product-category split and because MFDS's algorithm-documentation expectations do not map cleanly onto other regulators' frameworks.

Registration Dossier Requirements

• Administrative documents:
  • Import Item License application form (submitted online via UDIPORTAL)
  • KLH's Import Business License
  • Authorization letter from the foreign manufacturer, with Korean translation and original
  • Product summary description
• Technical documents:
  • Product performance test reports (electrical safety per the IEC 60601 series, biocompatibility per the ISO 10993 series, EMC, etc.)
  • Risk-management file (Korean standard equivalent to ISO 14971)
  • Clinical data/literature review — required by default for Class III/IV; Class II requirement depends on the specific product and predicate status
  • Software documentation (SaMD per IEC 62304, plus DMPA-specific documentation where applicable — see above)
• GMP documentation:
  • Valid ISO 13485 certificate, issued by an MDSAP-recognized body or an MFDS-recognized certification body, or
  • MFDS KGMP on-site inspection clearance
• Labeling and IFU:
  • Korean-language label specimen meeting all 14 mandatory elements under MFDS Notice 2022-110
  • Korean-language IFU covering the 11 core content areas described in Element 7
• Certificate of Free Sale (CFS):
  • CFS from the country of origin or primary marketing country, notarized/authenticated, stating marketing country(ies), product name, and manufacturer information
• IVD-specific additions: bridging-evidence documentation for foreign clinical/analytical data where applicable (see IVD section above)

Post-Market Surveillance, Adverse Event Reporting, and Recalls

• Adverse-event (vigilance) reporting: the KLH must be registered in MFDS's adverse-event monitoring system and report:
  • Death: within 15 days
  • Serious injury: within 30 days
  • Other events requiring attention: periodic/annual reporting
  • Foreign manufacturers fulfill these obligations through the KLH, not directly
• Recall rules: MFDS must be notified immediately upon recall initiation; recalls are classified Level I (life-threatening) / Level II (injury risk) / Level III (no direct hazard), each carrying different escalation and reporting expectations.
• Periodic safety/re-evaluation: Class III/IV products must submit periodic safety reports; designated product categories separately undergo periodic re-evaluation (주기적 재평가), generally on a ~5-year cycle post-market.
• Change management: product changes are split between changes requiring re-approval and changes that only require notification/filing — misclassifying a change either causes unnecessary re-approval delay or, worse, leaves a non-compliant change unfiled.
• IVD-specific: monthly supply reporting through the integrated MFDS system, on top of the general vigilance and recall duties above.

Import and Customs Requirements

• Import clearance: once a valid Import Item License is in place, the KLH (or a licensed importer operating under it) handles customs clearance using the license, commercial invoice, and packing list; the declared HS code must be consistent with the license.
• Customs requirements: HS code declaration is mandatory; the item-license number must accompany the customs filing; MFDS retains the ability to conduct post-clearance sampling/inspection on imported devices.
• Labeling language: Korean is mandatory on packaging at the point of market entry — see Element 7 for the full mandatory-content list; do not assume a post-import labeling grace window without confirming current MFDS/KLH practice.

Market Access Channels

Registration is the compliance entry point, not the commercial one — approval does not equal reimbursement or hospital purchasing access, and the two tracks should be planned in parallel rather than sequentially.

• Public hospital procurement: channelled through the Korean National Medical Device Information System and hospital procurement committees; university-affiliated hospitals and national tertiary hospitals are the primary channel for premium/high-end devices.
• Reimbursement listing (급여 등재): a separate application to the Health Insurance Review and Assessment Service (HIRA, 심사평가원) is required for insurance reimbursement listing, typically taking 6–12 months — and considerably longer, sometimes exceeding 2 years, for genuinely innovative or high-value devices where pricing negotiation is protracted.
• Private hospitals and specialist clinics: comparatively flexible and the preferred first channel for launching new products ahead of a broader public-channel push.
• E-commerce/online platforms: viable for low-risk consumer-grade devices (Class I/II) operating within MFDS's e-commerce regulatory guidelines.

Main Players and Channel Map

Market Entry Strategy and Key Risks

• Recommended KLH approach by strategic intent:
  • High-value, long-horizon products: favor an own subsidiary or an independent third-party KLH, both of which preserve registration continuity independent of any single distributor relationship.
  • Fast, lower-risk market tests (Class I/II): a distributor-held KLH can reasonably prioritize speed over long-term control, provided the manufacturer accepts the re-registration risk if the relationship ends.
• Confirm Abbreviated Review eligibility early: if the product holds FDA 510(k)/PMA clearance, the first strategic question before drafting the Korean dossier is whether the product category qualifies for Abbreviated Review (약식심사) — this should shape submission sequencing, not be discovered midway through review.
• Plan labeling and DMPA compliance ahead of submission, not at the end: the 14-element Korean labeling requirement and, for software products, the January 2026 DMPA product-category split should be resolved during dossier planning, not treated as a late-stage translation task.
• Key risks:
  • KLH lock-in risk: the registration is held by the KLH, not the manufacturer — contracts must explicitly address certificate-transfer/termination provisions before signing, not after a dispute arises.
  • Reimbursement-timeline risk: HIRA reimbursement negotiation for innovative/high-value devices can run well beyond a year, decoupling "MFDS-approved" from "commercially launched."
  • Domestic-competition risk: Korean device manufacturers are strong and improving quickly, particularly in ultrasound, endoscopy, dental, and AI-imaging segments — competitive positioning matters as much as regulatory clearance.
  • Local-testing lead-time risk: underestimating the 4–12 week local type-testing window (where required) is a common, avoidable cause of missed internal launch targets.
• Practical tips:
  • Use MFDS's formal 사전검토 (pre-review consultation) system to confirm classification, predicate/S.E. strategy, and Abbreviated Review eligibility before formal submission.
  • Ensure the KLH's Quality and Safety Manager has genuine, demonstrated MFDS submission experience — their response quality to RFI rounds is a direct driver of review speed.
  • KIMES (Korea International Medical & Hospital Equipment Show, annually in March, Seoul) remains a leading venue for market research and identifying KLH/distributor candidates.

Frequently Asked Questions

Who regulates medical devices in Korea?

The Ministry of Food and Drug Safety (MFDS, 식품의약품안전처) is Korea's national regulator for medical devices, drugs, and related products, operating under the Medical Devices Act. MFDS classifies devices into four risk classes, issues notifications/certifications/approvals, and delegates review of predicate-backed Class II (and select Class III) devices to one of six designated third-party reviewers, while retaining direct review authority for Class III/IV devices without a substantial-equivalent predicate.

What are Korea's medical device labeling requirements?

All medical device labels sold in Korea must be in Korean and must include 14 mandatory elements under MFDS Notice 2022-110 — product name, model, item-license number, KLH name and address, manufacturer name and address, manufacturing/expiration dates or lot number, storage conditions, MFDS-approved Korean warning phrasing, single-use/sterility indicators where applicable, and a reference to the IFU. A straight translation of an existing foreign-market label is explicitly not sufficient; labels must be built to Korea's own content and phrasing requirements.

Is local type testing required for medical devices in Korea?

Sometimes. Implantable, life-supporting, and genuinely novel devices without an established Korean predicate are the categories most likely to require local testing, along with electrical-safety and EMC testing for electrical devices. Foreign test data can generally substitute for local testing if it comes from a recognized/accredited laboratory and meets MFDS's specific testing criteria, but MFDS retains discretion to request supplemental local testing, particularly for novel technology. Local testing, where required, commonly takes 4–12 weeks.

How long does MFDS registration actually take?

Statutory processing targets are short on paper — roughly 5 working days for a Class I notification and 65–80 working days for MFDS-direct review — but real-world totals run far longer once RFI rounds and dossier pre-screening are included: 1–2 weeks for Class I, 3–6 months for Class II certification, 8–15 months for Class II/III approval, and 15–24 months for Class IV, with each RFI round typically adding 3–6 months.

What is a Korea License Holder (KLH), and is it mandatory?

Yes, mandatory. A foreign manufacturer cannot register directly with MFDS — it must appoint a KLH (an own Korean subsidiary, a local distributor, or an independent third-party KLH firm) that holds the Import Item License in its own name and controls who may import the device. Switching KLH requires a formal license-change filing or a fresh registration, so the choice of KLH model should be made deliberately, not defaulted to whichever distributor is signed first.

Does an existing FDA or CE approval speed up MFDS registration?

Partially, and it depends on the certificate. FDA 510(k)/PMA approval can qualify defined product categories for Abbreviated Review (약식심사), compressing 12–18 months toward roughly 4–8 months — a genuine formal acceleration, but only where the category is explicitly eligible. CE approval does not trigger a formal fast lane but is directly reusable as IMDRF-structured technical documentation and commonly supports the overseas-marketing-proof requirement. Neither approval waives the KLH requirement, Korean labeling, or KGMP evidence.

What is KGMP, and do I need it?

KGMP (품질관리기준, Korean Good Manufacturing Practice) applies to Class II–IV devices. MFDS will accept a valid ISO 13485 certificate issued by an MDSAP-recognized accreditation body as equivalent evidence, which can exempt the facility from a Korea-specific on-site inspection; otherwise MFDS conducts its own KGMP audit, typically completed within 2–3 months post-audit. KGMP certificates are valid for 3 years and must be renewed to keep the underlying product registration in good standing.

How are combination products regulated in Korea?

MFDS classifies combination products by their Primary Mode of Action (PMOA) — the single mode of action providing the product's most important therapeutic effect — which determines whether the Pharmaceutical Affairs Act (as a drug) or the Medical Devices Act (as a device) governs the product. MFDS issued dedicated combination-product review guidelines in November 2021 and a domestic/overseas classification casebook in April 2022; examples regulated as devices include drug-eluting stents and steroid-coated pacemaker electrodes, while pre-filled syringes and progestin-releasing IUDs are regulated as drugs.

Official Sources and Verification Dates

• Ministry of Food and Drug Safety — English portal: https://www.mfds.go.kr/eng/index.do (fetched and confirmed 2026-08-17)
• MFDS — Medical Device Approval Process (official, directly fetched): https://www.mfds.go.kr/eng/wpge/m_39/denofile.do (fetched and confirmed 2026-08-17; classification, notification/certification/approval structure, and review-day targets cross-checked here)
• Health Insurance Review and Assessment Service (HIRA): https://www.hira.or.kr/eng/ (accessed 2026-08-17)
• MFDS Notice 2026-6 comparison (combination/integrated/single-use device definitions, SaMD formal definition, DMPA labeling articles) — secondary summary: https://www.regdesk.co/blog/mfds-notice-2026-6-a-detailed-comparison-of-old-vs-new-medical-device-regulatory-requirements/ (accessed 2026-08-17)
• Korea medical device labeling requirements (MFDS Notice 2022-110, 14-element table, IFU content, eIFU) — secondary summary: https://leanabl.com/en/blog/korea-medical-device-labeling-rules (accessed 2026-08-17)
• South Korea local testing requirements (testing bodies, foreign-report acceptance, timelines) — secondary summary: https://omcmedical.com/blog/local-testing-medical-devices-south-korea (accessed 2026-08-17)
• Korea MFDS registration guide — KLH/KGMP context, 2026: https://www.mavenrs.com/blog/korea-mfds-medical-device-registration-guide-klh-kgmp-2026 (accessed 2026-08-17)
• South Korea medical device registration overview (classification, pathways, KLH, substantial-equivalence pathway) — secondary summary: https://elendilabs.com/en/articles/kr-medical-device (accessed 2026-08-17)
• South Korea IVD registration (classification, expedited third-party review, bridging evidence, KLH monthly reporting) — secondary summary: https://www.elendilabs.com/en/articles/kr-ivd (accessed 2026-08-17)
• Korea License Holder (KLH) role, ownership, and switching mechanics — secondary sources: https://www.freyrsolutions.com/medical-devices/korean-license-holder, https://omcmedical.com/blog/korea-license-holder-medical-devices, https://www.startcompanykorea.com/posts/korea-medical-device-import-license-klh-2026/ (accessed 2026-08-17)
• Combination products in South Korea (PMOA framework, November 2021 guideline, April 2022 casebook, examples) — secondary summary: https://www.freyrsolutions.com/blog/combination-products-in-south-korea-overview (accessed 2026-08-17)
• Digital Medical Products Act / digital therapeutics classification criteria — secondary summaries: https://www.regdesk.co/blog/mfds-korea-summary-of-revised-regulations-on-classification-and-designation-of-digital-medical-products/, https://www.koreabiomed.com/news/articleView.html?idxno=14995 (accessed 2026-08-17)
• Verification date: 2026-08-17

Items flagged for further verification (【待核验】)

• Exact current MFDS official application/review fee schedule by class (KRW figures in Element 5 and Quick Reference are compiled from secondary regulatory-services sources; the official MFDS fee calculator was not directly fetched during this verification pass).
• Whether the KLH's own Import Business License (수입업허가, entity-level) is subject to a periodic renewal cycle distinct from the per-product Import Item License's indefinite validity — secondary sources give inconsistent framing on this point.
• Exact scope of product categories eligible for MFDS's Abbreviated Review (약식심사) track — described here as category-specific and confirmable via MFDS guidelines or 사전검토 consultation, but no single authoritative eligible-category list was independently verified during this pass.
• Whether a post-import Korean-labeling grace window exists (some secondary sources for other Asian markets describe such windows; no equivalent was confirmed for Korea, and none should be assumed).